ABSTRACT
Characterisation of vulnerable neurons that die earliest with Alzheimer’s disease (AD) could provide rationale treatment targets to slow or prevent neurodegeneration. We used imaging mass cytometry to identify the neuronal sub-types lost earliest in AD and explored associated mechanisms with paired single nuclear transcriptomics in post-mortem middle temporal gyri from diseased donors. We found L5-6 RORB+ and L3-6 GAD1+ neurons show the greatest loss in AD. These neuronal subtypes also accumulated β-amyloids intracellularly. By contrast, pTau+ tangles progressively formed in a distinct L3 RORB+GPC5+ subtype that appeared resilient. Both astrocytes and microglia expressed reactive phenotype markers with AD and reactive microglia were spatially associated with vulnerable neurons. RORB+ neuronal sub-types accumulating either amyloids or pTau showed increased expression of autophagy-related genes. In conclusion, we identified layer- and neuronal subtype-specific loss with AD that suggest intrinsic autophagy-related defects associated with intracellular accumulation of β-amyloids, rather than pTau, may initiate early neurodegeneration.
Competing Interest Statement
This study was partly funded by Biogen IDEC. PMM has received consultancy fees from Sudo Biosciences, Ipsen Biopharm Ltd., Rejuveron Therapeutics and Biogen. He has received honoraria or speakers' fees from Novartis and Biogen and has received research or educational funds from BMS, Biogen, Novartis and GlaxoSmithKline.
Funding Statement
PMM acknowledges generous personal support from the Edmond J Safra Foundation and Lily Safra and an NIHR Senior Investigator Award. This work was supported by the UK Dementia Research Institute, which receives its funding from UK DRI Ltd., funded by the UK Medical Research Council, Alzheimer's Society, and Alzheimer's Research UK. AC salary and consumables were supported by the UK DRI Cross-centre post-doc programme.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Ethics committee of London Neurodegeneration [King's College London] gave ethical approval for this work. Ethics committee of Newcastle Brain Tissue Resource gave ethical approval for this work. Ethics committee of Queen's Square Brain Bank [University College London] gave ethical approval for this work. Ethics committee of Manchester Brain Bank gave ethical approval for this work. Ethics committee of Oxford Brain Bank gave ethical approval for this work. Ethics committee of South West Dementia Brain Bank [University of Bristol] gave ethical approval for this work. Ethics committee of Parkinson's UK [Imperial College London] Brain Bank gave ethical approval for this work.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
All data produced in the present study are available upon request to the authors.
